Radiopharmaceuticals use as a nuclear medicine for a Treatment of Disease


Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 15 | Issue : 01 | Page : –
    By

    Kailash Sahu,

  1. Principle, Department of Pharmacy, Vidhyapeeth Institute of Pharmacy Bhopal, Madhya Pradesh, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_176505’);});Edit Abstract & Keyword

Radiopharmaceuticals are radioactive substances that contain a bonded radionuclide with the intention of directing the radionuclide to a specific place for treatment or imaging. Radiopharmaceuticals are employed in nuclear medicine for cancer therapy as well as other therapeutic and diagnostic applications. Therefore, the primary goal of this study is to identify the key metal complexes and radioactive elements utilized in radiopharmaceutical applications. The sodium and methylenediphosphonate (MDP-99mTc) complexes, along with isotopes such as indium (111In), thallium (201Tl), gallium (67Ga, 68Ga), iodine (123I, 131I), chromium (51Cr), sulfur (35S), phosphorus (32P), and fluorine, are among the most significant radio-nuclear metal complexes used. These components have played a crucial role in enabling early medical detection, particularly with regard to cancer. At present, technetium complexes account for the larger share of radiopharmaceuticals in international use. Brazil’s Institute of Energy and Nuclear Research (IPEN) is a major producer, importer, and distributor of radiopharmaceuticals that supply clinics and hospitals across the country.

Keywords: Nuclear Research, diagnosis, isotopes, metal complexed, radio nuclear medicines

[This article belongs to Journal of Nuclear Engineering & Technology (jonet)]

How to cite this article:
Kailash Sahu. Radiopharmaceuticals use as a nuclear medicine for a Treatment of Disease. Journal of Nuclear Engineering & Technology. 2025; 15(01):-.
How to cite this URL:
Kailash Sahu. Radiopharmaceuticals use as a nuclear medicine for a Treatment of Disease. Journal of Nuclear Engineering & Technology. 2025; 15(01):-. Available from: https://journals.stmjournals.com/jonet/article=2025/view=0


document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_176505’);});Edit

References

  1. World Health Organization (WHO). (27 July 2023) Ionizing radiation and health effects. [Online]. Available from https://www.who.int/news-room/fact-sheets/detail/ionizing-radiation-and-health-effects
  2. Cherry, S. R., Sorenson, J. A., Phelps, M. E. Physicsin Nuclear Medicine. 4th Edition. Elsevier Inc.; China. 2012.
  3. International Atomic Energy Agency (IAEA). Operational guidance on hospital radiopharmacy: a safe and effective approach. Vienna: International Atomic Energy Agency, 2008. https://www-pub.iaea.org/MTCD/publications/PDF/Pub1342/Pub1342_web.pdf.
  4. Richard J. Kowalsky, Kara D. Weatherman. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 4th ed., American Pharmacists Association. Washington, D.C. 1852.
  5. Malley, M. C., Radioactivity: a history of a mysterious science, Oxford University Press, 1st Edition. New York, 2011.
  6. L’Annunziata, M. F., Radioactivity: introductionand history, from the quantum to quarks, Elsevier, 2nd ed., 2016. eBook ISBN: 9780444634962.
  7. Robilotta, C. C., A tomografia por emissão depósitrons: uma nova modalidade na medicina nuclearbrasileira, Rev. Panam. Salud Pública 20 (2/3) (2006)134-42. https://doi.org/10.1590/S1020-
  8. Santos-Oliveira, R., Carneiro-Leão, A. M. A., Ahistória da radiofarmácia e as implicações da EmendaConstitucionalnº49.Rev.Bras.Cienc.Farm.44(3) http://qnesc.sbq.org.br/online/cadernos/06/a08.pdf.
  9. Comissão Nacional de Energia Nuclear (CNEN),RMB e a Produção de Radiofármacos.http://www.cnen.gov.br/radiofarmacos.
  10. Wells, R. G., Instrumentation in molecular J. Nucl. Cardiol. 23 (6) 2016, 1343-1347.https://doi.org/10.1007/s12350-016-0498-z.
  11. WorldNuclearAssociation(WNA).Radionuclides(UpdatedNovember2018). http://www.world-nuclear.org/information-library/non-power-nuclear-applications/radionuclides-research/radionuclides-in-medicine.aspx.
  12. K, Seyed. Molecular Nuclear Imaging: TheRadiopharmaceuticals (Review) .Cancer Biotherapy andRadiopharmaceuticals, 20         (2)           https://doi.org/10.1089/cbr.2005.20.163.
  13. Comissão Nacional de Energia Nuclear (CNEN),Ministério da Ciência, Tecnologia, Inovação eComunicações, Relatório de Gestão do exercício de http://www.cnen.gov.br/images/cnen/documentos/acesso_a_informacao/Rel-gestao-2017.pdf.
  14. European Organization for Nuclear Research(CERN), A table of frequently used radioisotopes –CERN Document Server. C. Grupen, Introduction toRadiation Protection, Graduate Texts in Physics, 2010.https://doi.org/10.1007/978-3-642-02586-0.
  15. Wikimedia Commons, the free media repository, :Female_shadow_template.svg&oldid=302058264.
  16. AmazôniaAzulTecnologiasdeDefesaS.A.(Amazul), Reator    Multipropósito     https://www.marinha.mil.br/amazul/acesso-a-informacao/acoes-e-programas/programas/reator-multiproposito-brasileiro.
  17. Instituto de Pesquisas Energéticas e Nucleares(IPEN). Brazilian Multipurpose Reactor – Progress 6 p. 2016. PR_2014_2016_13_Brazilian_Multipurpose_Reactor.pdf.
  18. Pozzo, L., Coura Filho, G., Osso Júnior, J. A.,Squair, P. L., SUS in nuclear medicine in Brazil:analysis and comparison of data provided by DatasusandCNEN,Radiol.Bras.,47(3)(2014)141-148. https://doi.org/10.1590/0100-3984.2013.1906.
  19. Nuclear Energy   Agency  (NEA),    SteeringCommittee For Nuclear Energy, High-Level Group onthe Security of Supply of Medical Radioisotopes, The supply ofmedicalradioisotopes–2018medicalisotopedemandandcapacityprojectionforthe2018-2023http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=NEA/SEN/HLGMR(2018)3&docLanguage=En.
Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 13/01/2025
Accepted 20/02/2025
Published 04/03/2025
Publication Time 50 Days
138

async function fetchCitationCount(doi) {
let apiUrl = `https://api.crossref.org/works/${doi}`;
try {
let response = await fetch(apiUrl);
let data = await response.json();
let citationCount = data.message[“is-referenced-by-count”];
document.getElementById(“citation-count”).innerText = `Citations: ${citationCount}`;
} catch (error) {
console.error(“Error fetching citation count:”, error);
document.getElementById(“citation-count”).innerText = “Citations: Data unavailable”;
}
}
fetchCitationCount(“10.37591/JONET.v15i01.0”);

Loading citations…